- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Blood Safety and Quality Regulations 2005, Section 7.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
7.—(1) A blood establishment shall—
(a)ensure that the personnel directly involved in the collection, testing, processing, storage and distribution of human blood and blood components for the blood establishment are qualified to perform those tasks and are provided with timely, relevant and regularly updated training;
[F1(b)establish and maintain a quality system for blood establishments—
(i)in relation to Great Britain, that is based on the principles of good practice, which meets the standards and requirements set out in the Annex to Commission Directive 2005/62/EC and which gives effect to the Good Practice Guidelines for Blood Establishments Required to Comply with Directive 2005/62/EC published in the 20th edition of the Guide to the preparation, use and quality assurance of blood components;
(ii)in relation to Northern Ireland, that is based on the principles of good practice, which complies with the Community standards and requirements set out in the Annex to Commission Directive 2005/62/EC and which gives effect to the requirements in respect of the use of good practice guidelines set out in Article 2.2 of that Directive;]
(c)ensure that all testing and processes of the blood establishment which are referred to in Parts 2 to 5 of the Schedule are validated;
(d)maintain documentation on operational procedures, guidelines, training and reference manuals and reporting forms so that they are readily available for inspection under regulation 15;
F2(e). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(f)establish and maintain a procedure, which is accurate, efficient and verifiable, for the withdrawal from distribution of blood or blood components associated with any notification referred to in paragraph (e) [F3; and]
[F4(g)retain, for a period of at least 15 years, a record of any serious adverse events which may affect the quality or safety of blood and blood components.]
[F5(1A) In relation to Great Britain, for the purposes of paragraph (1)(b), references to the competent authority or to competent authorities in the Annex to Commission Directive 2005/62/EC must be read as references to the Secretary of State.]
(2) A blood establishment shall, in relation to the donation of blood—
(a)give all prospective donors of blood or blood components information in accordance with Part A of Part 2 of the Schedule;
(b)obtain from all persons who are willing to provide blood or blood components, information in accordance with Part B of Part 2 of the Schedule;
(c)put and keep in place procedures for the evaluation of donors;
(d)apply eligibility criteria for all donors of blood and blood components in accordance with Part 3 of the Schedule;
(e)maintain records of the results of donor evaluations and report to donors any relevant abnormal findings from the evaluations;
(f)ensure that—
(i)an examination of the donor, including an interview, is carried out before any donation of blood or blood components,
(ii)a qualified health professional is responsible for giving to and gathering from donors the information which is necessary to assess their eligibility to donate, and
(iii)on the basis of that information, a qualified health professional assesses the eligibility of all donors to donate; and
(g)encourage voluntary and unpaid blood donations with a view to ensuring that blood and blood components are, in so far as possible, provided from such donations, in particular, by—
(i)disseminating information about blood donation, and
(ii)advertising for blood donors.
(3) A blood establishment shall ensure that, in relation to the blood and blood components which it collects, processes, stores or distributes—
(a)each donation of blood and blood components (including blood and blood components which are imported [F6from a third country]) is tested in conformity with—
(i)the basic testing requirements for whole blood and apheresis donations, specified in paragraph (7), and
(ii)any additional tests which may be necessary for specific components, types of donors or epidemiological situations;
(b)the storage, transport and distribution conditions of blood and blood components comply with the requirements of Part 4 of the Schedule; and
(c)quality and safety requirements for blood and blood components meet the standards specified in Part 5 of the Schedule.
(4) A blood establishment shall, in relation to the activities specified in regulation 3(2) for which it is responsible, maintain records, for a minimum period of 15 years, of—
(a)the information specified in paragraphs (5) and (6),
(b)the conduct of the tests referred to in paragraph (3)(a).
(5) The information specified in this paragraph is—
(a)the total number of donors who give blood and blood components;
(b)the total number of donations;
(c)an updated list of the hospital blood banks which it supplies;
(d)the total number of whole donations not used;
(e)the number of each component produced and distributed;
(f)the incidence and prevalence of transfusion transmissible infectious markers in donors of blood and blood components;
(g)the number of product recalls; and
(h)the number of serious adverse events and serious reactions reported;
(6) The information specified in this paragraph is—
(a)information provided to donors by the blood establishment in accordance with paragraph (2)(a);
(b)information obtained from donors by the blood establishment in accordance with paragraph (2)(b); and
(c)information relating to the suitability of blood and plasma donors in accordance with the eligibility criteria specified in Part 3 of the Schedule.
(7) The basic testing requirements with which blood establishments must ensure compliance pursuant to paragraph (3)(a)(i) are—
(a)testing to establish ABO Group, except in respect of plasma intended only for fractionation;
(b)testing to establish Rh D Group, except in respect of plasma intended only for fractionation; and
(c)testing for the following infections of donors—
(i)Hepatitis B (HBs-Ag);
(ii)Hepatitis C (Anti-HCV);
(iii)HIV 1 and 2 (Anti-HIV 1 and 2).
(8) The Secretary of State may issue guidance as to the additional tests referred to in paragraph (3)(a)(ii) which are necessary in relation to specific components, types of donor or epidemiological situations and blood establishments shall have regard to such guidance.
(9) As soon as practicable after the end of the reporting year, each blood establishment shall provide to the Secretary of State a report specifying—
(a)the information referred to in paragraph (3) for that year; and
(b)details of the steps it has taken during that year to comply with paragraph (2)(g).
Textual Amendments
F1Reg. 7(1)(b) substituted (31.12.2020) by The Blood Safety and Quality (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/4), regs. 1, 7(a) (as substituted by S.I. 2020/1304, regs. 1, 7(a)); 2020 c. 1, Sch. 5 para. 1(1)
F2Reg. 7(1)(e) omitted (31.8.2006) by virtue of The Blood Safety and Quality (Amendment) Regulations 2006 (S.I. 2006/2013), regs. 1(1), 4(1)(b)
F3Word in reg. 7(1)(f) inserted (31.8.2006) by The Blood Safety and Quality (Amendment) Regulations 2006 (S.I. 2006/2013), regs. 1(1), 4(1)(c)
F4Reg. 7(1)(g) inserted (31.8.2006) by The Blood Safety and Quality (Amendment) Regulations 2006 (S.I. 2006/2013), regs. 1(1), 4(1)(d)
F5Reg. 7(1A) inserted (31.12.2020) by The Blood Safety and Quality (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/4), regs. 1, 7(b) (as amended by S.I. 2020/1304, regs. 1, 7(b)); 2020 c. 1, Sch. 5 para. 1(1)
F6Words in reg. 7(3)(a) substituted (31.12.2020) by The Blood Safety and Quality (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/4), regs. 1, 7(c); 2020 c. 1, Sch. 5 para. 1(1)
Modifications etc. (not altering text)
C1Reg. 7 modified (temp. until 30.6.2010) (16.12.2009) by The Blood Safety and Quality (Modification) Regulations 2009 (S.I. 2009/3307), regs. 1(1), 2
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: